Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States

被引：0
|
作者：
Shujing Zhang
Arielle G. Bensimon
Ruifeng Xu
Ruixuan Jiang
Alexandra Greatsinger
Adina Zhang
Mizuho Fukunaga-Kalabis
Clemens Krepler
机构：
[1] Merck & Co.,
[2] Inc.,undefined
[3] Analysis Group,undefined
[4] Inc.,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Adjuvant treatment; Cost-effectiveness analysis; Pembrolizumab; Stage IIB–IIC melanoma; US health sector perspective;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3038 / 3055
页数：17
相关论文
共 50 条
  • [21] Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
    Luke, Jason J.
    Ascierto, Paolo A.
    Khattak, Muhammad A.
    de la Cruz-Merino, Luis
    Del Vecchio, Michele
    Rutkowski, Piotr
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    de Galitiis, Federica
    Schadendorf, Dirk
    Carlino, Matteo S.
    Wu, Xi Lawrence
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M. M.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (14) : 1619 - 1624
  • [22] The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States
    Messali, Andrew
    Hay, Joel W.
    Villacorta, Reginald
    NEURO-ONCOLOGY, 2013, 15 (11) : 1532 - 1542
  • [23] THE COST-EFFECTIVENESS OF TEMOZOLOMIDE IN THE ADJUVANT TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA IN THE UNITED STATES
    Messali, A.
    Hay, J.
    Villacorta, R.
    VALUE IN HEALTH, 2012, 15 (04) : A221 - A222
  • [24] Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
    Luke, Jason J.
    Rutkowski, Piotr
    Queirolo, Paola
    Del Vecchio, Michele
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    de la Cruz-Merino, Luis
    Khattak, Muhammad A.
    Schadendorf, Dirk
    Long, Georgina, V
    Ascierto, Paolo A.
    Mandala, Mario
    De Galitiis, Federica
    Haydon, Andrew
    Dummer, Reinhard
    Grob, Jean-Jacques
    Robert, Caroline
    Carlino, Matteo S.
    Mohr, Peter
    Poklepovic, Andrew
    Sondak, Vernon K.
    Scolyer, Richard A.
    Kirkwood, John M.
    Chen, Ke
    Diede, Scott J.
    Ahsan, Sama
    Ibrahim, Nageatte
    Eggermont, Alexander M. M.
    LANCET, 2022, 399 (10336): : 1718 - 1729
  • [25] Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naive Patients with Advanced Melanoma in the United States
    Wang, Jingshu
    Chmielowski, Bartosz
    Pellissier, James
    Xu, Ruifeng
    Stevinson, Kendall
    Liu, Frank Xiaoqing
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (02): : 158 - 158
  • [26] A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma
    Messori, A
    Becagli, P
    Trippoli, S
    Tendi, E
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (09) : 1373 - 1379
  • [27] COST PER RECURRENCE-FREE SURVIVOR (CPRS) AND COST PER RECURRENCE-FREE LIFE MONTH (CPRLM) OF ADJUVANT NIVOLUMAB (NIVO) VERSUS PEMBROLIZUMAB (PEMBRO) AMONG PATIENTS WITH RESECTED STAGE IIB/IIC MELANOMA
    Davis, J. M.
    Srinivasan, S.
    Du, E. X.
    Xu, C.
    Linton, J.
    Betts, K.
    Shelley, K.
    VALUE IN HEALTH, 2024, 27 (06) : S65 - S65
  • [28] ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients
    Saam A. Mojtahed
    Nicole R. Boyer
    Saieesh A. Rao
    Thomas F. Gajewski
    Jennifer Tseng
    Kiran K. Turaga
    Annals of Surgical Oncology, 2021, 28 : 576 - 576
  • [29] ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients
    Mojtahed, Saam A.
    Boyer, Nicole R.
    Rao, Saieesh A.
    Gajewski, Thomas F.
    Tseng, Jennifer
    Turaga, Kiran K.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 3) : 576 - 576
  • [30] Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma
    Podlipnik, S.
    Moreno-Ramirez, D.
    Carrera, C.
    Barreiro, A.
    Manubens, E.
    Ferrandiz-Pulido, L.
    Sanchez, M.
    Vidal-Sicart, S.
    Malvehy, J.
    Puig, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 1190 - 1197
12345